title: Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
abstract: OBJECTIVE
  To investigate the potential use of accelerator mass spectrometry (AMS) in the study of the clinical pharmacology of imatinib.
  
  
  METHODS
  Six patients who were receiving imatinib (400 mg/d) as part of their ongoing treatment for chronic myeloid leukemia (CML) received a dose containing a trace quantity (13.6 kBq) of (14)C-imatinib. Blood samples were collected from patients before and at various times up to 72 h after administration of the test dose and were processed to provide samples of plasma and peripheral blood lymphocytes (PBL). Samples were analyzed by AMS, with chromatographic separation of parent compound from metabolites. In addition, plasma samples were analyzed by liquid chromatography/mass spectrometry (LCMS).
  
  
  RESULTS
  Analysis of the AMS data indicated that imatinib was rapidly absorbed and could be detected in plasma up to 72 h after administration. Imatinib was also detectable in PBL at 24 h after administration of the (14)C-labeled dose. Comparison of plasma concentrations determined by AMS with those derived by LCMS analysis gave similar average estimates of area under plasma concentration time curve (26 +/- 3 versus 27 +/- 11 microg/mL.h), but with some variation within each individual.
  
  
  CONCLUSIONS
  Using this technique, data were obtained in a small number of patients on the pharmacokinetics of a single dose of imatinib in the context of chronic dosing, which could shed light on possible pharmacologic causes of resistance to imatinib in CML.
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom. Alan.Boddy@ncl.ac.uk
authors.forename: Alan V
authors.initials: AV
authors.lastname: Boddy
authors.forename: Julieann
authors.initials: J
authors.lastname: Sludden
authors.forename: Melanie J
authors.initials: MJ
authors.lastname: Griffin
authors.forename: Colin
authors.initials: C
authors.lastname: Garner
authors.forename: John
authors.initials: J
authors.lastname: Kendrick
authors.forename: Pritesh
authors.initials: P
authors.lastname: Mistry
authors.forename: Catherine
authors.initials: C
authors.lastname: Dutreix
authors.forename: David R
authors.initials: DR
authors.lastname: Newell
authors.forename: Stephen G
authors.initials: SG
authors.lastname: O'Brien
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D010315:Particle Accelerators; D010879:Piperazines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000493:pharmacokinetics* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate